Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in November
Foghorn Therapeutics (Nasdaq: FHTX) announced that management will participate in three investor conferences in November, with CEO Adrian Gottschalk presenting.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Foghorn Therapeutics (Nasdaq: FHTX) announced that management will participate in three investor conferences in November, with CEO Adrian Gottschalk presenting.
The Guggenheim fireside chat is November 10 at 3:30 p.m. ET; the Stifel presentation is November 11 at 10:00 a.m. ET; and the Jefferies London fireside chat is November 16 at 4:30 p.m. GMT. Management will also hold one-on-one meetings at each conference.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines against challenging targets in oncology and immunology & inflammation, today announced that management will participate in the Guggenheim Third Annual Healthcare Innovation Conference, Stifel 2026 Healthcare Conference, and Jefferies 2026 London Healthcare Conference.
Guggenheim Third Annual Healthcare Innovation Conference
- Fireside Chat: Tuesday, November 10, 2026, at 3:30 p.m. ET
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Registration link: Register here
- Management will also participate in one-on-one meetings
Stifel 2026 Healthcare Conference
- Presentation: Wednesday, November 11, 2026, at 10:00 a.m. ET
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Management will also participate in one-on-one meetings
Jefferies 2026 London Healthcare Conference
- Fireside Chat: Monday, November 16, 2026, at 4:30 p.m. GMT
- Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Management will also participate in one-on-one meetings
A webcast of the Guggenheim fireside chat can be accessed under “Events & Presentations” in the Investors section of the Company’s website here and will be available for 90 days.
About Foghorn Therapeutics
Foghorn® Therapeutics is a biotechnology company developing novel medicines against challenging biological targets through multiple modalities and approaches, including oral small molecules, targeted protein degradation and induced proximity. The Company is advancing programs in oncology as well as immunology & inflammation. Foghorn brings together deep biological understanding and small-molecule drug discovery expertise to pursue challenging targets with selectivity. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com
